Recurrent Respiratory Papillomatosis (RRP) Clinical Trials

RRP is caused by 2 low-risk types of human papillomavirus, HPV 6 and HPV 11, the same types that cause genital warts. The virus infects the lining of the airway and produces benign growths called papillomas, most often on the vocal cords. They can spread down the windpipe and, rarely, into the lungs, and in a small number of patients they turn cancerous.

The most common symptoms of Recurrent Respiratory Papillomatosis include Hoarseness or a changing voice, the most common symptom, Noisy breathing, especially when breathing in, Shortness of breath or trouble breathing as growths narrow the airway, Chronic cough, Trouble swallowing, among others. In the US, CDC estimates put new cases at 2 or fewer per 100,000 children and 2 to 3 per 100,000 adults (NIDCD), and the FDA counts about 1,000 new cases a year. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Recurrent Respiratory Papillomatosis from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Adults with RRP now have an FDA-approved option, Papzimeos, given as 4 injections under the skin over 12 weeks after the growths are removed. A second immunotherapy, INOVIO's Voceryq (INO-3107), a DNA medicine given as 4 injections into a muscle, usually the upper arm, received FDA accelerated approval for adults on October 30, 2026.

Yes. As of October 21, 2026, 2 FDA-approved medicines have a current label that names Recurrent Respiratory Papillomatosis: Papzimeos (zopapogene imadenovec), first approved in 2025; and Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), first approved in 2026. Corticosteroids and immune globulins count once each.

Recurrent Respiratory Papillomatosis is an acquired condition, not an inherited one. Caused by infection with HPV types 6 and 11, not by an inherited gene change. In the US, CDC estimates put new cases at 2 or fewer per 100,000 children and 2 to 3 per 100,000 adults (NIDCD), and the FDA counts about 1,000 new cases a year.

Eligibility for Recurrent Respiratory Papillomatosis clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Recurrent Respiratory Papillomatosis clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.